BMO Capital Markets Reiterates “Buy” Rating for Pfizer, Inc. (NYSE:PFE)

Pfizer, Inc. (NYSE:PFE)‘s stock had its “buy” rating reiterated by analysts at BMO Capital Markets in a research report issued on Thursday, September 14th. They currently have a $37.00 target price on the biopharmaceutical company’s stock. BMO Capital Markets’ price objective points to a potential upside of 3.93% from the stock’s current price.

Several other equities analysts have also commented on the stock. Credit Suisse Group lowered shares of Pfizer from an “outperform” rating to a “neutral” rating and decreased their price objective for the company from $38.00 to $36.00 in a research report on Thursday, July 20th. Zacks Investment Research raised shares of Pfizer from a “sell” rating to a “hold” rating in a research report on Friday, July 14th. Morgan Stanley reaffirmed a “neutral” rating and issued a $35.00 price objective (down from $38.00) on shares of Pfizer in a research report on Monday, June 12th. Vetr downgraded shares of Pfizer from a “buy” rating to a “hold” rating and set a $35.71 price target on the stock. in a report on Wednesday, September 13th. Finally, ValuEngine downgraded shares of Pfizer from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $38.04.

Shares of Pfizer (PFE) opened at 35.60 on Thursday. Pfizer has a 12 month low of $29.83 and a 12 month high of $36.21. The firm has a market capitalization of $211.73 billion, a P/E ratio of 26.04 and a beta of 1.00. The firm’s 50-day moving average is $33.78 and its 200 day moving average is $33.53.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The business had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The company’s quarterly revenue was down 1.9% on a year-over-year basis. During the same period in the prior year, the firm posted $0.64 earnings per share. On average, equities research analysts anticipate that Pfizer will post $2.56 EPS for the current year.

WARNING: “BMO Capital Markets Reiterates “Buy” Rating for Pfizer, Inc. (NYSE:PFE)” was first reported by StockNewsTimes and is the property of of StockNewsTimes. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://stocknewstimes.com/2017/09/29/pfizer-inc-pfe-stock-rating-reaffirmed-by-bmo-capital-markets.html.

In other news, CEO Ian C. Read sold 96,950 shares of Pfizer stock in a transaction on Friday, August 4th. The stock was sold at an average price of $34.00, for a total transaction of $3,296,300.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Laurie J. Olson sold 8,064 shares of Pfizer stock in a transaction on Monday, August 21st. The stock was sold at an average price of $32.70, for a total value of $263,692.80. Following the transaction, the insider now owns 74,506 shares in the company, valued at approximately $2,436,346.20. The disclosure for this sale can be found here. Insiders sold a total of 464,521 shares of company stock worth $15,813,961 in the last 90 days. 0.06% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of PFE. Janus Henderson Group PLC raised its holdings in shares of Pfizer by 243.5% during the 2nd quarter. Janus Henderson Group PLC now owns 13,175,187 shares of the biopharmaceutical company’s stock worth $442,574,000 after acquiring an additional 9,339,749 shares during the period. Vanguard Group Inc. raised its holdings in shares of Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock worth $14,062,088,000 after acquiring an additional 9,239,499 shares during the period. Renaissance Technologies LLC purchased a new position in shares of Pfizer during the 2nd quarter worth $268,389,000. Canada Pension Plan Investment Board raised its holdings in shares of Pfizer by 249.6% during the 2nd quarter. Canada Pension Plan Investment Board now owns 10,713,626 shares of the biopharmaceutical company’s stock worth $359,871,000 after acquiring an additional 7,649,416 shares during the period. Finally, Parametric Portfolio Associates LLC increased its position in shares of Pfizer by 42.1% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 17,818,368 shares of the biopharmaceutical company’s stock worth $598,519,000 after purchasing an additional 5,281,314 shares during the last quarter. Institutional investors and hedge funds own 69.00% of the company’s stock.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Analyst Recommendations for Pfizer (NYSE:PFE)




Receive News & Ratings for Pfizer Inc. Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer Inc. and related companies with MarketBeat.com’s FREE daily email newsletter.

Leave a Reply

Your email address will not be published.

four × five =